Ildong Pharmaceutical Co., Ltd. (KRX:249420)
South Korea · Delayed Price · Currency is KRW 14,330
-480 (-3.24%)
Oct 8, 2026, 10:50 AM KST
Ildong Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 451,510 | 1,213,061 | 328,764 | 502,483 | 764,721 | 799,187 | |
Market Cap Growth | -47.32% | 268.98% | -34.57% | -34.29% | -4.31% | 77.78% |
Enterprise Value | 524,800 | 1,310,725 | 467,886 | 480,579 | 872,139 | 869,595 |
Last Close Price | 14810.00 | 38245.45 | 11692.18 | 18039.93 | 28361.24 | 33377.85 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 10.77 | 43.85 | - | - | - | - |
Forward PE | - | 14.76 | 14.76 | 14.76 | 14.76 | 14.76 |
PS Ratio | 0.80 | 2.14 | 0.54 | 0.84 | 1.20 | 1.43 |
PB Ratio | 1.79 | 4.94 | 1.98 | 2.80 | 3.75 | 4.79 |
P/TBV Ratio | 1.97 | 5.42 | 2.48 | 3.75 | 4.96 | 7.37 |
P/FCF Ratio | 20.80 | 228.70 | 18.67 | - | - | - |
P/OCF Ratio | 13.17 | 64.01 | 11.62 | - | - | - |
PEG Ratio | - | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.93 | 2.31 | 0.76 | 0.80 | 1.37 | 1.55 |
EV/EBITDA Ratio | 11.16 | 32.85 | 12.52 | - | - | - |
EV/EBIT Ratio | 20.53 | 75.67 | 40.93 | - | - | - |
EV/FCF Ratio | 24.07 | 247.12 | 26.56 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.50 | 0.59 | 1.24 | 1.19 | 1.02 | 1.36 |
Debt / EBITDA Ratio | 2.75 | 3.62 | 5.50 | - | - | - |
Debt / FCF Ratio | 5.85 | 27.23 | 11.67 | - | - | - |
Net Debt / Equity Ratio | 0.27 | 0.32 | 0.73 | 0.73 | 0.63 | 0.43 |
Net Debt / EBITDA Ratio | 1.49 | 1.99 | 3.23 | -5.24 | -2.92 | -2.85 |
Net Debt / FCF Ratio | 3.16 | 14.98 | 6.85 | -2.64 | -1.97 | -2.75 |
Asset Turnover | 1.02 | 0.98 | 1.02 | 0.95 | 0.94 | 0.85 |
Inventory Turnover | 3.63 | 3.69 | 4.42 | 4.23 | 4.44 | 3.97 |
Quick Ratio | 0.56 | 0.51 | 0.52 | 0.41 | 0.44 | 0.59 |
Current Ratio | 1.06 | 0.99 | 0.92 | 0.69 | 0.91 | 0.84 |
Return on Equity (ROE) | 18.50% | 11.51% | -7.17% | -42.25% | -76.68% | -47.91% |
Return on Assets (ROA) | 2.79% | 1.86% | 1.19% | -5.27% | -6.75% | -5.17% |
Return on Invested Capital (ROIC) | 6.54% | 4.23% | 3.82% | -16.60% | -25.79% | -18.97% |
Return on Capital Employed (ROCE) | 7.20% | 5.00% | 3.60% | -19.80% | -21.30% | -15.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 9.35% | 2.28% | -1.39% | -15.71% | -18.52% | -12.48% |
FCF Yield | 4.81% | 0.44% | 5.36% | -9.91% | -8.55% | -3.25% |
Dividend Yield | 1.40% | 0.52% | - | - | - | - |
Payout Ratio | 14.45% | 0.22% | - | - | - | - |
Buyback Yield / Dilution | -16.43% | -10.01% | -3.34% | -2.61% | -10.76% | 0.00% |
Total Shareholder Return | -15.08% | -9.49% | -3.34% | -2.61% | -10.76% | 0.00% |